drug ineffective; suspected covid-19/sars-cov-2 infection; this is a spontaneous report received from a contactable reporter (consumer or other non hcp) from the regulatory authority and product quality group. the reporter is the patient. a 62 year-old female patient received bnt162b2 (comirnaty), administration date 06oct2021 (lot number: ff8222) as dose 3 (booster), single, (batch/lot number: unknown) as dose 2, single and (batch/lot number: unknown) as dose 1, single for covid-19 immunisation. relevant medical history included: "hiatus hernia" (unspecified if ongoing), notes: take medication when necessary; "breathlessness" (unspecified if ongoing). the patient's concomitant medications were not reported. patient has not had symptoms associated with covid-19. the patient reporter that she is generally fit and well. but is still recovering from covid and frequently very tired and breathless, also experiences aching in leg. the following information was reported: drug ineffective (medically significant) with onset 29dec2021, outcome "recovered" (07jan2022), described as "drug ineffective"; suspected covid-19 (medically significant) with onset 29dec2021, outcome "recovered" (07jan2022), described as "suspected covid-19/sars-cov-2 infection". clinical course: patient was not enrolled in clinical trial. the report did not relate to possible inflammation of heart (myocarditis or pericarditis). the patient underwent the following laboratory tests and procedures: sars-cov-2 test: no - negative covid-19 test. no follow-up attempts are possible. no further information is expected.; sender's comments: linked report(s) : gb-pfizer inc-202200329298 same patient,product,different dose/event

test name: covid-19 virus test; result unstructured data: test result:no - negative covid-19 test

na

na